DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for VT-X7, Osteal Therapeutics€™ (Osteal€™s€) investigational drug...
President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award follows the announcement by Osteal of an oversubscribed $23M...
Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM Capital, Prism Ventures and Medvest Capital. Proceeds...
Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection
Osteal Therapeutics Announces Leadership Team Appointments
DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for musculoskeletal infections, announced today it has completed enrollment of 76 subjects for its U.S. Phase 2 clinical trial of VT-X7 for the treatment of periprosthetic joint infections of the hip or knee. Results from this trial will be used to support a U.S. New Drug Application following completion of Osteal’s clinical development program.
Series B financing led by HM Capital and joined by returning investors JJDC and Medvest Capital Proceeds will support clinical development of lead candidate, VT-X7 for periprosthetic joint infection....